A Randomized, Two Arm, Open Label, Comparative, single centre study to evaluate efficacy and safety of 2 formulations of telmisartan in patients with type 2 diabetes and hypertension

Troikaa Pharmaceuticals Limited0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Adult patients aged 18-65 years.
•2.Diabetic with FPG >= 126 mg/dl (7.0 mmol/l)
•3.Patients with Stage I hypertension (JNC 7 guidelines)
•4.Newly diagnosed treatment naÃ¯ve/ currently untreated hypertension or patients unable to tolerate current antihypertensive therapy.

•1.Age below 18 years and above 65 years
•2.Stage 2 hypertension (JNC 7 guidelines)
•3.Secondary hypertension
•4.Any acute medical condition
•5.Uncontrolled diabetes mellitus
•6.Baseline laboratory values outside the clinically acceptable limits
•7.Pregnant women and lactating mothers
•8.Females of child bearing age not practicing contraception or not willing to use barrier contraceptive
•9.Patients or relatives unwilling to give written informed consent
•10.Participation in a clinical study involving an investigational product within past 30 days.
•11.Known hypersensitivity to telmisartan/ ARB or any component of the formulations.

发起方